
(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Ocean side Objections: Staggering Waterfront Breaks - 2
Former 'Bachelorette' welcomes 1st baby via emergency c-section - 3
Which Startup's Innovation Could Reform Medical care? - 4
6 Fun Urban areas For Seniors To Travel - 5
How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
Manual for Tracking down Spending plan Agreeable Travel Objections
Scientists Just Discovered Japan’s First New Bird Species in Over 40 Years
Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
How to watch 'A Charlie Brown Christmas' for free in 2025
Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
Rescuers attempt to dig free whale stranded on Germany's Baltic coast
This cafe takes orders in sign language. It's cherished by the Deaf community
'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff












